Skip to main content
. Author manuscript; available in PMC: 2023 Jul 23.
Published in final edited form as: Pharmacotherapy. 2023 Feb 14;43(7):609–621. doi: 10.1002/phar.2774

Table 4: Association of Target Attainment in Early Sepsis and in Late Sepsis with Hospitalization Characteristics and Outcomes.

Target defined as Concentrations above 1x Clinical Laboratory Standards Institute (CLSI) breakpoint/MIC for 100% dosing interval.

Early Sepsis Target Attainment Late Sepsis Target Attainment
Overall Cohort
n=55
Did not Attain
Target
n=2
Attained Target
n=53
p-value Did not Attain
Target
n=10
Attained Target
n=45
p-value
Number of Patients for whom Q24h dosing initiated in Early Sepsis 6 (10.9%) 2 (100%) 4 (7.5%) 0.010 4 (40%) 2 (4.4%) 0.0076
Number of Patients who had Q24h dosing in Late Sepsis (initiated or continued from Early Sepsis) 15 (27.3%) 2 (100%) 13 (24.5%) 0.071 10 (100%) 5 (11.1%) <0.001
Number of Patients with Each Dosing Regimen in Phase of Interest
Q24h -- 2 (100%) 4 (7.5%) 0.010 10 (100%) 5 (11.1%) <0.001
Q12h 0 (0%) 49 (92.5%) 0 (0%) 40 (89%)
Age (years) Median (IQR) 7.5 (1.5, 13.8) 4.1 (3.6, 4.7) 8.2 (1.5, 13.8) 0.64 2.2 (1.5, 4.7) 8.2 (1.7, 13.8) 0.33
PRISM III Score Median (IQR) 3.0 (0.5, 6.5) 1.0 (0.5, 1.5) 3.0 (1.0, 7.0) 0.18 2.0 (0, 5.3) 3.0 (2.0, 7.0) 0.34
PICU LOS (days) Median (IQR) 4.0 (2.0, 7.5) 2.5 (1.8, 3.3) 4.0 (2.0, 8.0) 0.24 2.0 (1.3, 3.5) 5.0 (3.0, 8.0) 0.0067
Hospital LOS (days) Median (IQR) 13.0 (8.0, 24.0) 14.0 (12.5, 15.5) 13.0 (8.0, 26.0) 0.87 19.5 (8.8, 26.8) 12.0 (8.0, 18.0) 0.51
Days on Vasopressor in PICU Median (IQR) 1.0 (1.0, 2.0) N/A (0 on pressors) 1.0 (1.0, 2.0) -- 1.0 (1.0, 1.0) 1.0 (1.0, 2.0) 0.72
Vasopressor-Free Days in PICU Median (IQR) 4.0 (2.0, 7.5) 2.5 (1.8, 3.3) 4.0 (2.0, 8.0) 0.31 2.0 (1.0, 3.5) 5.0 (2.0, 8.0) 0.015
Days on Ventilator in Hospital 5.0 (3.0, 13.0) N/A (0 on ventilator) 5.0 (3.0, 13.0) -- 1.0 (1.0, 7.0) 5.5 (3.0, 15.8) 0.22
Ventilator-Free Days in PICU Median (IQR) 2.0 (1.0. 2.5) 2.5 (1.8, 3.3) 2.0 (1.0, 2.0) 0.58 1.5 (1.0, 2.0) 2.0 (1.0, 3.0) 0.58
Sepsis Type
Culture-negative 40 (73%) 2 (100%) 38 (72%) 1 7 (70%) 33 (73%) 1
Culture-positive 15 (27%) 0 (0%) 15 (28%) 3 (30%) 12 (27%)
Presence of Comorbidities
No 18 (33%) 1 (50%) 17 (32%) 1 2 (20%) 16 (36%) 0.47
Yes 37 (67%) 1 (50%) 36 (68%) 8 (80%) 29 (64%)
Complicated Sepsis
No 52 (94.5%) 2 (100%) 50 (94.3%) 1 10 (100%) 42 (93%) 1
Yes 3 (5.5%) 0 (0%) 3 (5.7%) 0 (0%) 3 (7%)
Acute Kidney Injury in Early Sepsis
No 33 (60%) 2 (100%) 31 (59%) 0.51 7 (70%) 26 (58%) 0.72
Yes 22 (40%) 0 (0%) 22 (41%) 3 (30%) 19 (42%)
Acute Kidney Injury in Late Sepsis
No 40 (73%) 2 (100%) 38 (72%) 1 8 (80%) 32 (71%) 0.71
Yes 15 (27%) 0 (0%) 15 (285) 2 (20%) 13 (29%)
Total Parental Nutrition Use
No 50 (91%) 2 (100%) 13 (25%) 0.071 7 (70%) 43 (96%) 0.037
Yes 5 (9%) 0 (0%) 40 (75%) 3 (30%) 2 (4%)
Days on Ceftriaxone Median (IQR) 7.0 (4.0, 8.0) 8.0 (6.5, 9.5) 7.0 (4.0, 8.0) 0.51 7.0 (5.0, 9.3) 6.0 (4.0, 8.0) 0.72
Broaden Antibiotics
No 45 (82%) 1 (50%) 44 (83%) 0.33 5 (50%) 40 (89%) 0.012
Yes 10 (18%) 1 (50%) 9 (17%) 5 (50%) 5 (11%)
Fever Duration (days) Median (IQR) 2.0 (1.0, 3.0) 4.5 (3.8, 5.3) 2.0 (1.0, 3.0) 0.11 2.5 (2.0, 3.8) 2.0 (1.0, 3.0) 0.068
Number of Repeat Cultures in 7 days Median (IQR) 1.0 (0.0, 6.0) 2.0 (1.0, 3.0) 1.0 (0.0, 2.0) 0.68 2.0 (1.0, 2.0) 0.0 (0.0, 2.0) 0.087
Number of CRP in 7 days Median (IQR) 0.0 (0.0, 1.0) 3.5 (1.8, 5.3) 0.0 (0.0, 1.0) 0.39 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.72
Number of Procalcitonin 7 days Median (IQR) 1.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.076 0.5 (0.0, 1.0) 1.0 (0.0, 1.0) 0.21